A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

FDA Approves New-Age NON-OPIOID Pain Relief Formula That Does NOT Shut Down Your Vital Organs Via Heroin Addiction. NEWS ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic medicine. The recent FDA approval of Journavx, a non-opioid acute pain ...

While the approval of Journavx (suzetrigine) has gained much positivity in non-opioid pain management, former FDA medical officer in the division of psychiatry, Josef Witt-Doerring, M.D., warns that ...

Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...